ロード中...
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
Edoxaban, a factor Xa inhibitor, was approved by the United States Food and Drug Administration in 2015 for stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism. It is the fourth target-specific oral anticoagulant to be approved. Edoxaban is noninferior for ef...
保存先:
| 出版年: | Ther Clin Risk Manag |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4853158/ https://ncbi.nlm.nih.gov/pubmed/27217759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S84608 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|